Avails Medical
Developer of an electronic biosensor platform for rapid phenotypic antimicrobial susceptibility testing (AST). Technology measures redox (oxidation-reduction) changes from pathogen metabolism to generate standardized inocula directly from positive blood cultures, aiming to shorten laboratory turnaround time for AST and integrate with existing disk diffusion and automated AST workflows. Activities include instrument and consumable development, multicenter clinical evaluations, and regulatory submissions.
Industries
Nr. of Employees
small (1-50)
Avails Medical
1080 O’Brien Drive, Suite A Menlo Park, CA 94025 USA
Patents
Apparatus, systems, and methods for preparing an output sample comprising a defined concentration of an infectious agent for downstream testing
US-12422343-B2
View DetailsDevices, systems and methods to detect the presence of ß-lactam antibiotic hydrolyzing bacteria in a sample
US-12352714-B2
View DetailsDevices, systems and methods to detect viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives
US-12275982-B2
View DetailsApparatus, systems, and methods for determining the concentration of microorganisms and the susceptibility of microorganisms to anti-infectives based on redox reactions
US-12275981-B2
View Details
Apparatus, systems, and methods for preparing an output sample comprising a defined concentration of an infectious agent for downstream testing
US-12422343-B2
View DetailsDevices, systems and methods to detect the presence of ß-lactam antibiotic hydrolyzing bacteria in a sample
US-12352714-B2
View DetailsDevices, systems and methods to detect viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives
US-12275982-B2
View DetailsApparatus, systems, and methods for determining the concentration of microorganisms and the susceptibility of microorganisms to anti-infectives based on redox reactions
US-12275981-B2
View DetailsProducts
eQUANT System
Bench-top instrument and disposable reagent tube system that generates a 0.5 McFarland equivalent suspension directly from positive blood cultures in approximately 64–72 minutes for use with downstream phenotypic AST methods (disk diffusion and automated AST).
eQUANT System
Bench-top instrument and disposable reagent tube system that generates a 0.5 McFarland equivalent suspension directly from positive blood cultures in approximately 64–72 minutes for use with downstream phenotypic AST methods (disk diffusion and automated AST).
Expertise Areas
- Rapid phenotypic antimicrobial susceptibility testing
- Biosensor platform development for pathogen quantification
- Clinical study design and multicenter validation of diagnostics
- Regulatory submission and clearance (FDA 510(k))
Key Technologies
- Potentiometric oxidation-reduction potential (ORP) sensing
- Electronic biosensors for microbial metabolism
- Automated inoculum standardization to 0.5 McFarland
- Signal-processing and decision algorithms for density estimation
News & Updates
Announcement of FDA 510(k) clearance for the eQUANT system for direct AST use with a defined panel of gram-negative organisms and disk diffusion.
Announcement of submission of the inoculum generation system to the U.S. FDA for 510(k) clearance.
Announcement of the start of a U.S. pilot trial for the company's rapid AST system.
Announcement of Dan Douglas joining the company as Vice President of Finance.
Award of additional non-dilutive funding from CARB-X to support development of a rapid electronic AST platform.
Publication reporting multicenter evaluation of the system for disk diffusion AST directly from positive blood cultures, including performance metrics and time-savings.
Announcement of FDA 510(k) clearance for the eQUANT system for direct AST use with a defined panel of gram-negative organisms and disk diffusion.
Announcement of submission of the inoculum generation system to the U.S. FDA for 510(k) clearance.
Announcement of the start of a U.S. pilot trial for the company's rapid AST system.
Announcement of Dan Douglas joining the company as Vice President of Finance.
Award of additional non-dilutive funding from CARB-X to support development of a rapid electronic AST platform.
Publication reporting multicenter evaluation of the system for disk diffusion AST directly from positive blood cultures, including performance metrics and time-savings.